Tilda Orami (Papua New Guinea)
Papua New Guinea Institute of Medical Research
Infection and Immunity
I joined the PNG Institute of Medical Research as a Medical Laboratory Technician with certificate in Medical Technology in 1995. I went back to studies. In 2009, and completed my Bachelors in Medical Laboratory Science. I have worked in different studies conducted by the Institute in the infectious disease such as typhoid fever, HIV and sexual transmitted infection and paediatric meningitis. I have also worked with the two major pneumococcal conjugate vaccines trials (PCV7 and PCV10/13) conducted by the institute in the country and most part my time spend in the institute was involved with the vaccine trial. I was mainly processing and testing samples that can be done from these studies in the Immunology and Bacteriology laboratories. I have presented in in-house seminars, within the country had also done poster presentations at three ISPPD conferences. I have also co-authored on some publication on the work that I worked with. I am currently working as a Medical Technologist in the Bacteriology Laboratory in a study of neonates given probiotics within 72 hours after birth and each day up to the 7th day of their life and do follow ups to age 6 months.

Presenter of 1 Presentation

 Conference Calendar

O094 - IMPACT OF PCV10 AND PCV13 ON PNEUMOCOCCAL CARRIAGE AND PNEUMOCOCCAL ANTIMICROBIAL SUSCEPTIBILITY IN PAPUA NEW GUINEAN CHILDREN (ID 607)

Session Name
0760 - Parallel Session 11: New Perspectives on Pneumococcal Colonization (ID 65)
Session Type
Parallel Session
Date
Wed, 22.06.2022
Session Time
15:05 - 16:35
Room
Grand Ballroom West
Presenter
Lecture Time
15:40 - 15:50

Abstract

Background

In the first head-to-head trial conducted in a low-income country, 262 Papua New Guinean infants were randomized to receive PCV10 or PCV13 in a 1-2-3-month schedule. One and 6-month post-vaccination pneumococcal carriage rates remained high (≥ 87%), 20% of pneumococci being PCV10/PCV13-shared serotype and 10% PCV13-only. We now report pneumococcal carriage rates 20 months post-vaccination and antimicrobial susceptibility of pneumococci carried 1-20 months post-vaccination.

Methods

Nasopharyngeal swabs were cultured using standard bacteriological procedures. Antimicrobial susceptibility was determined by Kirby-Bauer disc diffusion and minimum inhibition concentrations.

Results

Overall pneumococcal carriage rates 20 months post-vaccination were comparable for PCV10 (93.6%, 86.6-97.6%) and PCV13 (88.6%, 80.1-94.4%) recipients, but PCV10/PCV13-shared serotypes carriage rates tended to be lower in PCV13 recipients (9.3%, 4.1-17.5%) than PCV10 recipients (19.8%, 12.2-29.5%), as was carriage of PCV13-only serotypes (PCV13: 4.7%, 1.3-11.5%) (PCV10: 12.1%, 6.2-20.6%). Of the pneumococci carried in either vaccine group 1-, 6- and 20-months post-vaccination, 42.0%, 46.7%, and 45.9% were non-susceptible to penicillin, and 39.2%, 43.9%, and 37.2% non-susceptible to trimethoprim-sulfamethoxazole (TMP/SXT), respectively. PCV serotypes 19A, 19F, and 23F were in the top 5 most-commonly carried pneumococci (4.1%, 4.1%, and 5.6%, respectively), and were associated with high non-susceptibility to penicillin (19A, 70%; 19F, 75%) and/or TMP/SXT (19A, 80%; 19F, 50%; 23F, 61%).

Conclusions

Pneumococcal carriage rates remain high in PNG children, even after PCV vaccination, due to the broad range of carriage serotypes (71 serotypes) and limited effect of PCVs on carriage. Serotype-independent vaccines are needed to reduce the burden of pneumococcal disease in such settings.

Hide